Genelux (GNLX) Long-Term Debt Issuances (2023)

Genelux (GNLX) posted quarterly Long-Term Debt Issuances of $215000.0 for Q4 2023, up 200.0% quarter-over-quarter from -$215000.0 in Q3 2023.

Genelux (GNLX) Long-Term Debt Issuances (2023) Analysis & Trends

Genelux's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $215000.0 for Q4 2023.

In Q4 2023, Long-Term Debt Issuances changed N/A year-over-year to $215000.0; the TTM figure through Dec 2023 stood at $900000.0 (changed N/A YoY), while the FY2023 annual figure was $900000.0, down 18.18% from the prior year.
Long-Term Debt Issuances for Q4 2023 stood at $215000.0, up from -$215000.0 in the prior quarter.
The five-year high for Long-Term Debt Issuances was $900000.0 in Q1 2023, with the low at -$215000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Genelux	119.87 Mn	119.87 Mn	-	-

Download Data